UK-based consumer health company Clinova initiates a UK study into the effectiveness of its oral rehydration solution (ORS) in Covid-19 patients suffering with acute viral upper respiratory infection symptoms. These symptoms include coughing, fevers, and nasal congestion.

ORS is an over-the-counter drug composed of a combination of glucose and salt,  dissolved in water to rehydrate patients.

Clinova co-founder and research and development director Arsalan Karim said: “While this product cannot cure Covid-19 symptoms, we hope it will be shown to significantly decrease the significant amount of discomfort suffered by patients.

“While prevention of the virus through steps such as social distancing, handwashing, and continued worldwide research into a vaccine, it must not be forgotten that there is much to be done to reduce discomfort in sufferers.

“Hydration is one of the most important aspects of human health, especially when the body is faced with challenges such as extreme heat or illness. Good hydration goes a long way in supporting the body’s natural ability to defend and repair, which is going to be incredibly important for anyone suffering with Covid-19 symptoms.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.